- Kuida CBD skincare products to be distributed through 2,350
stores across four drug store health and beauty distributor groups
in Spain
- Deal with Red Yellow Red, a
leading cosmetic products master distributor, representing access
to a combined 20,000 stores in Spain and Portugal
- Kuida product training, CBD category education, and brand
promotional activity to support drug store distribution
- Spain represented a total
skincare market of €1.5 billion in 2018 and is expected to reach
€1.8 billion by 2023 (Source: Euromonitor - Passport)
TORONTO, July 2, 2020 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, announced that it has signed a
distribution deal for its Kuida™ CBD cosmeceutical
brand with Red Yellow Red, a leading
EU distributor of cosmetic products. Kuida skin and body care
products for women will be distributed by Red Yellow Red through four major multinational
drug store health and beauty distribution groups in Spain.
"The European skincare market is the largest in the world, and
as we scale up our EU activity this agreement immediately expands
our Kuida footprint into a €1.5 billion market. Red Yellow Red have a large and compelling
distribution network, and a robust sales and education program that
aligns with our proven market entry approach to help more consumers
integrate Kuida into their daily skincare regimen," comments
Tejinder Virk, President, Khiron
Europe.
Red Yellow Red is a specialized
distributor of cosmetic, beauty, lifestyle and personal wellbeing
products operating in Spain and
Portugal, with access to 20,000
points of sale through four drug store health and beauty
distributor groups. To support Kuida sales and brand image,
Red Yellow Red will initiate
training of retail staff on the current Kuida portfolio, the
benefits of cannabidiol (CBD), as well as the brand's unique
CBDERM™ technology. Further Red Yellow Red information can be found at
http://www.redyellowred.es/.
"At Red Yellow Red we look to
bring innovative and first to market products to our distribution
partners and in turn, consumers. Kuida fits that model and is an
established skincare brand with an attractive CBD product line
that, supported by our training and education program, can have
strong appeal across our Spanish pharmacy network," comments José
Luis Ganado, Managing Director,
Red Yellow Red.
About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis
company with core operations in Latin
America, and operational activity in Europe and North
America. Khiron is the leading cannabis company in
Colombia and the first company
licensed in Colombia for the
cultivation, production, domestic distribution, and international
export of both low and high THC medical cannabis products. The
Company has presence in Mexico,
Peru, Uruguay, Brazil, UK, Spain and Germany, where it is positioned to begin sales
of medical cannabis.
Leveraging its first-mover advantage, and patient oriented
approach, Khiron combines global scientific expertise, product
innovation, agricultural infrastructure, wholly-owned medical
clinics, and online doctor education programs to drive prescription
and brand loyalty to address priority medical conditions. Its
Wellbeing unit launched the first branded CBD skincare brand in
Colombia, with Kuida™
now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is
led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at www.khiron.ca, investors.khiron.ca and on
Instagram @khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-expands-eu-footprint-signing-kuida-distribution-deal-in-spain-301087361.html
SOURCE Khiron Life Sciences Corp.